According to the article, Quest Diagnostics not only shares its wealth with shareholders in the form of dividends, the company also regularly increases that payout. Since 2011, the quarterly dividend has ramped up from 10 cents per share to 45 cents per share now.
Quest also has high hopes that the next year will be noticeably better than the current. At an Investor Day event in November, Quest Diagnostics upped its 2017-20 revenue growth outlook to between 3% and 5% per annum.
Other companies on this list include Gilead Sciences, Inc. (NASDAQ:GILD), UnitedHealth Group Inc (NYSE:UNH), Stryker Corporation (NYSE:SYK), Allergan plc (NYSE:AGN), Medical Properties Trust, Inc. (NYSE:MPW), Cryolife Inc (NYSE:CRY), Incyte Corporation (NASDAQ:INCY), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and Merck & Co., Inc. (NYSE:MRK).
